Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :390
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded149    
    Comments [Add]    

Recommend this journal


Year : 2017  |  Volume : 54  |  Issue : 3  |  Page : 547-549

Short-term efficacy and safety of apatinib in advanced squamous cell carcinoma of the lung

1 Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou 277100, China
2 Department of Neurology, Xuzhou Central Hospital, Xuzhou 277100, China

Correspondence Address:
Dr. Liang Han
Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou 277100
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijc.IJC_379_17

Rights and Permissions

OBJECTIVE: To evaluate the short-term efficacy and safety of apatinib alone or combined with chemotherapy in the treatment of advanced squamous cell lung cancer. METHODS: Forty patients with advanced squamous cell lung carcinoma were enrolled in this study, who were treated in Xuzhou Central Hospital from 2014 to 2015. All patients underwent first-line or more chemotherapy. Patients were administrated with apatinib 425 mg/day, alone or combined with chemotherapy. The short-term efficacy was evaluated according to the RECIST criteria. The main safety event was evaluated by CTC-AE criteria. RESULTS: Among all the 40 patients, partial response in 5 cases, stable disease in 24 cases, progressive disease in 11 cases, overall response rate in 12.5%, disease control rate in 72.5%, the median progression-free survival was 3.7 months. The main adverse events were leukopenia, fatigue, and hypertension. Most of the adverse events were grade I and II level. CONCLUSION: The use of apatinib alone or combined with chemotherapy in patients with advanced or metastatic squamous cell lung carcinoma demonstrates a high response rate, favorable tolerability profile.


Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow